Search

Your search keyword '"Meszaros, Martina"' showing total 30 results
Start Over Author "Meszaros, Martina"
30 results on '"Meszaros, Martina"'

10. Effect of Nocturnal Oxygen on Blood Pressure Response to Altitude Exposure in COPD – Data from a Randomized Placebo-Controlled Cross-Over Trial

Author

Meszaros,Martina, Latshang,Tsogyal D, Aeschbacher,Sayaka S, Huber,Fabienne, Flueck,Deborah, Lichtblau,Mona, Ulrich,Stefanie, Hasler,Elisabeth D, Scheiwiller,Philipp M, Reinhard,Lukas, Ulrich,Silvia, Bloch,Konrad E, Furian,Michael, and Schwarz,Esther I

Subjects
International Journal of Chronic Obstructive Pulmonary Disease
Abstract

Martina Meszaros,1 Tsogyal D Latshang,1 Sayaka S Aeschbacher,1 Fabienne Huber,1 Deborah Flueck,1 Mona Lichtblau,1 Stefanie Ulrich,1 Elisabeth D Hasler,1 Philipp M Scheiwiller,1 Lukas Reinhard,1 Silvia Ulrich,1,2 Konrad E Bloch,1– 3 Michael Furian,1 Esther I Schwarz1,3 1Department of Pulmonology and Sleep Disorders Centre, University Hospital Zurich, Zurich, Switzerland; 2Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland; 3Centre of Competence Sleep & Health, University of Zurich, Zurich, SwitzerlandCorrespondence: Esther I SchwarzDepartment of Pulmonology and Sleep Disorders Centre, University Hospital Zurich, Zurich, SwitzerlandTel +41 44 255 11 11Fax +41 44 255 44 51Email estherirene.schwarz@usz.chPurpose: Patients with chronic obstructive pulmonary disease (COPD) are particularly vulnerable to hypoxia-induced autonomic dysregulation. Hypoxemia is marked during sleep. In COPD, altitude exposure is associated with an increase in blood pressure (BP) and a decrease in baroreflex-sensitivity (BRS). Whether nocturnal oxygen therapy (NOT) may mitigate these cardiovascular autonomic changes in COPD at altitude is unknown.Materials and Methods: In a randomized placebo-controlled cross-over trial, 32 patients with moderate-to-severe COPD living < 800 m were subsequently allocated to NOT and placebo during acute exposure to altitude. Measurements were done at low altitude at 490 m and during two stays at 2048 m on NOT (3 L/min) and placebo (3 L/min, ambient air) via nasal cannula. Allocation and intervention sequences were randomized. Outcomes of interest were BP, BRS (from beat-to-beat BP measurement), BP variability (BPV), and heart rate.Results: About 23/32 patients finished the trial per protocol (mean (SD) age 66 (5) y, FEV1 62 (14) % predicted) and 9/32 experienced altitude-related illnesses (8 vs 1, p < 0.05 placebo vs NOT). NOT significantly mitigated the altitude-induced increase in systolic BP compared to placebo (Δ median − 5.8 [95% CI − 22.2 to − 1.4] mmHg, p = 0.05) but not diastolic BP (− 3.5 [95% CI − 12.6 to 3.0] mmHg; p = 0.21) or BPV. BRS at altitude was significantly higher in NOT than in placebo (1.7 [95% CI 0.3 to 3.4] ms/mmHg, p = 0.02).Conclusion: NOT may protect from hypoxia-induced autonomic dysregulation upon altitude exposure in COPD and thus protect from a relevant increase in BP and decrease in BRS. NOT may provide cardiovascular benefits in COPD during conditions of increased hypoxemia and may be considered in COPD travelling to altitude.Keywords: COPD, altitude, oxygen, hypoxia, blood pressure, blood pressure variability, baroreflex sensitivity

Published
2021

11. Effect of oxygen on blood pressure response to altitude exposure in COPD

Author

Meszaros, Martina, primary, Latshang, Tsogayl D, additional, Aeschbacher, Sayaka, additional, Huber, Fabienne, additional, Flueck, Deborah, additional, Lichtblau, Mona, additional, Ulrich, Stefanie, additional, Hasler, Elisabeth D, additional, Scheiwiller, Philipp, additional, Ulrich, Silvia, additional, Bloch, Konrad, additional, Furian, Michael, additional, and Schwarz, Esther Irene, additional

Published
2021
Full Text
View/download PDF

13. Highlights of the ERS Lung Science Conference and Sleep and Breathing Conference 2021 and the new ECMC members

Author

Goodwin, Amanda T., primary, Karadoğan, Dilek, additional, De Santis, Martina M., additional, Alsafadi, Hani N., additional, Hawthorne, Ian, additional, Bradicich, Matteo, additional, Siciliano, Matteo, additional, Şahin Duyar, Sezgi, additional, Targa, Adriano, additional, Meszaros, Martina, additional, Fanaridis, Michail, additional, Gille, Thomas, additional, Keir, Holly R., additional, Moor, Catharina C., additional, Lichtblau, Mona, additional, Ubags, Niki D., additional, and Cruz, Joana, additional

Published
2021
Full Text
View/download PDF

17. Lumbar Spine Abnormalities in Patients With Obstructive Sleep Apnoea

Author

Tarnoki, Adam Domonkos, primary, Tarnoki, David Laszlo, additional, Oláh, Csaba, additional, Szily, Marcell, additional, Kovacs, Daniel, additional, Dienes, András, additional, Piroska, Marton, additional, Forgo, Bianka, additional, Pinheiro, Marina, additional, Ferreira, Paulo, additional, Kostyál, László, additional, Meszaros, Martina, additional, Pako, Judit, additional, Kunos, Laszlo, additional, and Bikov, Andras, additional

Published
2021
Full Text
View/download PDF

30. Triglyceride-Glucose Index in Non-Diabetic, Non-Obese Patients with Obstructive Sleep Apnoea.

Author

Bikov, Andras, Frent, Stefan M., Meszaros, Martina, Kunos, Laszlo, Mathioudakis, Alexander G., Negru, Alina Gabriela, Gaita, Laura, Mihaicuta, Stefan, and Roche, Frédéric

Subjects
SLEEP apnea syndromes, BODY mass index, INSULIN resistance, LIPID analysis, GENDER
Abstract

Obstructive sleep apnoea (OSA) is associated with increased insulin resistance. Triglyceride-glucose index (TyG) is a simple marker of insulin resistance; however, it has been investigated only by two studies in OSA. The aim of this study was to evaluate TyG in non-diabetic, non-obese patients with OSA. A total of 132 patients with OSA and 49 non-OSA control subjects were included. Following a diagnostic sleep test, fasting blood was taken for the analysis of the lipid profile and glucose concentrations. TyG was calculated as ln(triglyceride [mg/dL] × glucose [mg/dL]/2). Comparison analyses between OSA and control groups were adjusted for age, gender, body mass index (BMI) and smoking. TyG was higher in men (p < 0.01) and in ever-smokers (p = 0.02) and it was related to BMI (ρ = 0.33), cigarette pack-years (ρ = 0.17), apnoea–hypopnoea index (ρ = 0.38), oxygen desaturation index (ρ = 0.40), percentage of total sleep time spent with oxygen saturation below 90% (ρ = 0.34), and minimal oxygen saturation (ρ = −0.29; all p < 0.05). TyG values were significantly higher in OSA (p = 0.02) following adjustment for covariates. OSA is independently associated with higher TyG values which are related to disease severity in non-obese, non-diabetic subjects. However, the value of TyG in clinical practice should be evaluated in follow-up studies in patients with OSA. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results